Biodefense and Infectious Disease
Emerging infectious diseases such as Zika virus, influenza, yellow fever, or respiratory syncytial virus (RSV) continue to pose a threat to public health both in the US and abroad. In addition, certain infectious agents have the potential to be used for bioterrorism purposes when aerosolized, such as Bacillus anthracis (anthrax) and Yersinia pestis (plague).
IITRI has supported the US Government’s efforts to defend against the growing threats of bioterrorism and emerging infectious diseases for over 40 years. As a premier infectious disease contract research organization (CRO), we offer a wide range of services to evaluate the immunogenicity, efficacy, potency, and safety of vaccines, antitoxins and therapeutics protecting against agents of biological warfare and bioterrorism.
We offer an extensive collection of infectious disease animal models that are available for efficacy testing of therapeutic antibiotics or antivirals and vaccines. We also offer complete GLP-compliant preclinical vaccine toxicology programs and Animal Rule studies.
Our laboratory and vivarium space includes Biosafety Level 2 and 3+ facilities, fully functional with the latest equipment to conduct pathogenic agent studies. We are registered with the CDC and USDA for possession and use of select agents and toxins. In addition, we have the distinction of being one of only two non-government laboratories that operates a Department of the Army approved Biological Surety Program.
Our BSL-3 lab houses our bioaerosol generation and exposure system for viral challenge or antiviral therapeutic efficacy studies using aerosolized pathogen infection.
In vitro Assays
- RT-PCR and full suite of PCR-based assays
- ELISA, RIA, Western, EpiAirway
- Assay development, validation and performance